drugset / Trial / NCT02482298

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

NCT02482298

Phase 2 Completed 87 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

Timeline

Start
2015-07-09
Primary completion
2016-11-16
Completion
2016-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 10 mg Oral
Subject Ticagrelor Small molecule 45 mg Oral

Indications